At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo 62% of patients treated with TEPEZZA had. | April 10, 2023
Mucormycosis risk mitigation in the COVID battle
Updated:
Updated:
May 13, 2021 23:46 IST
Diabetes control can lower the chances of dangerous side-effects in COVID-19 treatment such as this fungal infection
Share Article
AAA
Diabetes control can lower the chances of dangerous side-effects in COVID-19 treatment such as this fungal infection
The COVID-19 pandemic continues to play havoc all over the world and India is no exception to this. While 70%-80% of those affected with COVID-19 recover without many side-effects, about 20%-30% of patients affected with symptomatic COVID-19 might require hospitalisation here, a minority can get worse and require treatment in an intensive care unit (ICU). Ever since the COVID-19 pandemic was first described from Wuhan in China, it is quite clear that it is people with comorbidities such as being of an older age, obese, having uncontrolled diabetes, heart or respiratory diseases and malignancies, who fare badly.